Oral: Jin Li, et al. HLX04 (a bevacizumab biosimilar candidate) versus reference bevacizumab in combination with XELOX or mFOLFOX6 as first-line therapy for metastatic colorectal cancer: a randomised, double-blind phase 3 study

Shukui Qin, Jin Li, et al. Efficacy and safety of HLX10, a novel anti-PD-1 antibody, in patients with previously treated unresectable or metastatic microsatellite instability-high or mismatch repair-deficient solid tumors: A single-arm, multicenter, phase 2 study. Journal of Clinical Oncology 2021 39:15_suppl, 2566-2566. DOI: 10.1200/JCO.2021.39.15_suppl.2566

Lingying Wu, et al. Efficacy and safety evaluation of HLX10 (a recombinant humanized anti-PD-1 monoclonal antibody) combined with albumin-bound paclitaxel in patients with advanced cervical cancer who have progressive disease or intolerable toxicity after first-line standard chemotherapy: A single-arm, open-label, phase 2 study. Journal of Clinical Oncology 2021 39:15_suppl, e17510-e17510. DOI: 10.1200/JCO.2021.39.15_suppl.e17510

Zeng X, et al. AB0197 EFFICACY AND SAFETY OF HLX01 COMBINED WITH METHOTREXATE IN CHINESE PATIENTS WITH MODERATELY TO SEVERELY ACTIVE RHEUMATOID ARTHRITIS WHO HAD INADEQUATE RESPONSES TO METHOTREXATE: RESULTS OF A RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 STUDY. Annals of the Rheumatic Diseases 2021;80:1122-1123. DOI:10.1136/annrheumdis-2021-eular.282

Shi Y, et al. Phase 1 studies comparing safety, tolerability, pharmacokinetics and pharmacodynamics of HLX01 (a rituximab biosimilar) to reference rituximab in Chinese patients with CD20-positive B-cell lymphoma. Chin J Cancer Res 2021;33(3):405-416. DOI: 10.21147/j.issn.1000-9604.2021.03.11

A phase 1 randomized study compare the pharmacokinetics, safety and immunogenicity of HLX04 to reference bevacizumab sourced from the United States, the European Union, and China in healthy Chinese male volunteers. Cancer Chemotherapy and Pharmacology. http://doi.org/10.1007/s00280-021-04297-z